Zydus Cadila inks alliance pact with German firm Pieris

The Ahmedabad-based Zydus Cadila has entered into an alliance with Germany-based Pieris AG, a next generation therapeutic protein R&D company, for development and commercialisation of multiple novel Anticalin-based protein therapeutics. Pieris AG is an independent, clinical-stage biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that are safer and more effective than conventional approaches.
 
The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing. Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal pre-clinical development and into clinical development, undertaking drug development in accordance with ICH guidelines. Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets.
 
ALSO READ: Clariant India's Roha plant receives cGMP certification

Pankaj Patel, Chairman and Managing Director, Zydus Group, said, “Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus’ ongoing transformation into an innovation-led global healthcare provider, and we are pleased to add Anticalins to our novel biologics pipeline.”
 
Stephen Yoder, CEO, Pieris, added, “With Zydus’ state-of-the-art manufacturing facilities and seasoned drug development team, this collaboration will allow Pieris to unlock value on a global scale in a cost-effective manner, significantly expanding the number of proprietary Anticalin programs we can advance into clinical trials.”
 
ALSO READ: Chinese pharma intermediates may become uncompetitive compared to India: Ashwin Shroff, Excel Industries Ltd

The most advanced program in the collaboration is PRS-110, an Anticalin specific for c-Met, a target becoming increasingly validated across a broad spectrum of tumours. PRS-110, which is a pure antagonist due to its monovalent target engagement, has demonstrated the ability to inhibit both ligand-dependent and -independent c-Met activity in a variety of animal models. Through this unique collaborative model, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories at the appropriate time. The companies will share licensing revenues on mutually agreed-upon terms.